Brian Patrick Brennan, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Obsessive-Compulsive Disorder | 18 | 2022 | 1442 | 2.680 |
Why?
|
Glutamic Acid | 4 | 2017 | 1168 | 1.010 |
Why?
|
Glutamine | 3 | 2017 | 574 | 0.920 |
Why?
|
Gyrus Cinguli | 4 | 2017 | 1086 | 0.800 |
Why?
|
Residential Treatment | 4 | 2018 | 111 | 0.680 |
Why?
|
Antidepressive Agents | 5 | 2017 | 2836 | 0.490 |
Why?
|
Citalopram | 1 | 2017 | 404 | 0.490 |
Why?
|
Acetylcarnitine | 1 | 2013 | 9 | 0.480 |
Why?
|
Thioctic Acid | 1 | 2013 | 23 | 0.470 |
Why?
|
Performance-Enhancing Substances | 1 | 2013 | 29 | 0.440 |
Why?
|
Behavior Therapy | 1 | 2018 | 865 | 0.430 |
Why?
|
Anabolic Agents | 2 | 2015 | 247 | 0.420 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2017 | 3757 | 0.400 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2017 | 1127 | 0.390 |
Why?
|
Psychiatric Status Rating Scales | 7 | 2018 | 6028 | 0.380 |
Why?
|
Doping in Sports | 1 | 2010 | 63 | 0.370 |
Why?
|
Self Medication | 1 | 2010 | 117 | 0.370 |
Why?
|
Riluzole | 1 | 2009 | 55 | 0.360 |
Why?
|
Bipolar Disorder | 4 | 2021 | 5023 | 0.330 |
Why?
|
Memantine | 1 | 2008 | 100 | 0.310 |
Why?
|
Dopamine Agents | 1 | 2008 | 190 | 0.300 |
Why?
|
Androgens | 2 | 2015 | 1270 | 0.300 |
Why?
|
Implosive Therapy | 2 | 2018 | 118 | 0.290 |
Why?
|
Bulimia Nervosa | 1 | 2008 | 176 | 0.290 |
Why?
|
Cerebral Cortex | 3 | 2021 | 5721 | 0.280 |
Why?
|
Human Growth Hormone | 1 | 2010 | 683 | 0.260 |
Why?
|
Depressive Disorder, Major | 3 | 2021 | 4606 | 0.260 |
Why?
|
Mental Disorders | 2 | 2022 | 6570 | 0.250 |
Why?
|
Thiophenes | 1 | 2009 | 589 | 0.250 |
Why?
|
Irritable Bowel Syndrome | 1 | 2009 | 441 | 0.230 |
Why?
|
Synaptic Transmission | 1 | 2009 | 1177 | 0.230 |
Why?
|
Athletes | 1 | 2010 | 1086 | 0.220 |
Why?
|
Human Development | 2 | 2021 | 124 | 0.220 |
Why?
|
Analgesics | 1 | 2009 | 1034 | 0.210 |
Why?
|
Internet | 1 | 2013 | 3048 | 0.190 |
Why?
|
Public Health | 1 | 2013 | 2587 | 0.180 |
Why?
|
Cerebrum | 1 | 2020 | 137 | 0.170 |
Why?
|
Brain | 8 | 2020 | 26345 | 0.170 |
Why?
|
Young Adult | 11 | 2021 | 56255 | 0.150 |
Why?
|
Adult | 22 | 2022 | 213394 | 0.140 |
Why?
|
Extinction, Psychological | 1 | 2018 | 375 | 0.130 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 3636 | 0.130 |
Why?
|
Thinking | 1 | 2018 | 320 | 0.130 |
Why?
|
Fetal Development | 1 | 2021 | 763 | 0.130 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 4239 | 0.120 |
Why?
|
Neurosciences | 1 | 2018 | 347 | 0.120 |
Why?
|
Linear Models | 2 | 2014 | 5948 | 0.110 |
Why?
|
Adolescent | 10 | 2022 | 85405 | 0.110 |
Why?
|
Sarcoma, Synovial | 1 | 2014 | 164 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 35326 | 0.110 |
Why?
|
Phosphocreatine | 1 | 2013 | 270 | 0.110 |
Why?
|
Neural Pathways | 3 | 2019 | 2976 | 0.110 |
Why?
|
Humans | 32 | 2022 | 739398 | 0.110 |
Why?
|
Male | 20 | 2021 | 349022 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2019 | 8977 | 0.100 |
Why?
|
Middle Aged | 12 | 2021 | 212863 | 0.100 |
Why?
|
Disability Evaluation | 2 | 2009 | 1824 | 0.100 |
Why?
|
Female | 17 | 2021 | 378853 | 0.100 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15511 | 0.090 |
Why?
|
Resilience, Psychological | 1 | 2017 | 650 | 0.090 |
Why?
|
Deep Brain Stimulation | 1 | 2018 | 746 | 0.090 |
Why?
|
Consumer Health Information | 1 | 2013 | 209 | 0.090 |
Why?
|
Fear | 1 | 2018 | 1430 | 0.090 |
Why?
|
Testosterone | 2 | 2011 | 2391 | 0.090 |
Why?
|
Mitochondria | 2 | 2013 | 3522 | 0.090 |
Why?
|
Protons | 1 | 2015 | 1124 | 0.090 |
Why?
|
Antipsychotic Agents | 1 | 2022 | 3055 | 0.080 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2018 | 1424 | 0.080 |
Why?
|
Psychometrics | 1 | 2018 | 2995 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2018 | 62693 | 0.080 |
Why?
|
Time Factors | 4 | 2018 | 40050 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7788 | 0.080 |
Why?
|
Motivation | 1 | 2017 | 1965 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3510 | 0.070 |
Why?
|
Erectile Dysfunction | 1 | 2011 | 458 | 0.070 |
Why?
|
Brain Mapping | 2 | 2019 | 6666 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6478 | 0.070 |
Why?
|
Neuropsychological Tests | 2 | 2015 | 6963 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1359 | 0.060 |
Why?
|
Oxygen | 1 | 2015 | 4158 | 0.060 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2008 | 895 | 0.060 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2010 | 2015 | 0.050 |
Why?
|
Stress, Psychological | 1 | 2017 | 4212 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2896 | 0.050 |
Why?
|
Schizophrenia | 1 | 2021 | 6866 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2014 | 3945 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2017 | 13880 | 0.050 |
Why?
|
Compulsive Personality Disorder | 1 | 2021 | 48 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2011 | 2040 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2015 | 4026 | 0.050 |
Why?
|
Knowledge | 1 | 2021 | 174 | 0.040 |
Why?
|
Pain Measurement | 1 | 2009 | 3419 | 0.040 |
Why?
|
Systems Analysis | 1 | 2020 | 170 | 0.040 |
Why?
|
Quality of Life | 4 | 2018 | 12640 | 0.040 |
Why?
|
Child | 6 | 2022 | 77033 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2021 | 937 | 0.040 |
Why?
|
Psychopathology | 1 | 2020 | 395 | 0.040 |
Why?
|
Research Report | 1 | 2020 | 351 | 0.040 |
Why?
|
Benzodiazepines | 1 | 2022 | 1099 | 0.040 |
Why?
|
Pilot Projects | 1 | 2009 | 8275 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2022 | 1409 | 0.030 |
Why?
|
Aged | 5 | 2022 | 162698 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2021 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 976 | 0.030 |
Why?
|
Child, Preschool | 3 | 2022 | 40802 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1583 | 0.030 |
Why?
|
Organ Size | 1 | 2020 | 2247 | 0.030 |
Why?
|
Longevity | 1 | 2022 | 1066 | 0.030 |
Why?
|
Models, Psychological | 1 | 2018 | 809 | 0.030 |
Why?
|
Inositol | 1 | 2015 | 216 | 0.030 |
Why?
|
Hypertrophy | 1 | 2015 | 565 | 0.030 |
Why?
|
Thalamus | 1 | 2019 | 1020 | 0.030 |
Why?
|
Genes, Mitochondrial | 1 | 2012 | 61 | 0.030 |
Why?
|
Prefrontal Cortex | 1 | 2022 | 2138 | 0.030 |
Why?
|
Free Radical Scavengers | 1 | 2012 | 218 | 0.020 |
Why?
|
Depression | 1 | 2011 | 7689 | 0.020 |
Why?
|
Nootropic Agents | 1 | 2012 | 160 | 0.020 |
Why?
|
Comorbidity | 2 | 2018 | 10362 | 0.020 |
Why?
|
Body Mass Index | 1 | 2008 | 12655 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2021 | 21694 | 0.020 |
Why?
|
Oxidative Phosphorylation | 1 | 2012 | 479 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2018 | 19811 | 0.020 |
Why?
|
Gels | 1 | 2010 | 426 | 0.020 |
Why?
|
Prospective Studies | 2 | 2014 | 53037 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3506 | 0.020 |
Why?
|
Glycolysis | 1 | 2012 | 825 | 0.020 |
Why?
|
Israel | 1 | 2011 | 794 | 0.020 |
Why?
|
Europe | 1 | 2014 | 3331 | 0.020 |
Why?
|
Amygdala | 1 | 2015 | 1303 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2011 | 11985 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 1585 | 0.020 |
Why?
|
Obesity | 1 | 2008 | 12643 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8669 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2012 | 940 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2011 | 740 | 0.020 |
Why?
|
Down-Regulation | 1 | 2012 | 2999 | 0.020 |
Why?
|
Up-Regulation | 1 | 2012 | 4205 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 24714 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2012 | 3087 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13872 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10945 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 40389 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 57650 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 38942 | 0.010 |
Why?
|
Animals | 1 | 2018 | 168368 | 0.000 |
Why?
|
United States | 1 | 2011 | 69573 | 0.000 |
Why?
|